T2 Biosystems (NASDAQ: TTOO)
T2 Biosystems Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
T2 Biosystems Company Info
T2 Biosystems, Inc. engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.
News & Analysis
Why Shares of T2 Biosystems Are Falling Friday
A revenue drop and a reverse stock split worried investors.
Why T2 Biosystems Stock Soared Today
The diagnostic test maker's panels could help to combat the spread of new coronavirus variants.
Why T2 Biosystems Stock Is Soaring Today
Investors are excited about the prospects of the company's COVID-19 diagnostic test.
Here's Why T2 Biosystems Rose as Much as 16% Today
The diagnostic innovator provided performance data for a product pipeline candidate aimed at diagnosing Lyme disease.
Here's Why T2 Biosystems, Inc. Rose Over 16% Today
The diagnostic company is rebounding after a stock offering.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.